

Alison M Schram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5300946/publications.pdf>

Version: 2024-02-01

44
papers

6,613
citations

218677

26
h-index

254184

43
g-index

44
all docs

44
docs citations

44
times ranked

12578
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
2	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	27.8	572
3	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411
4	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 963-972.	9.4	331
5	A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. <i>Nature Genetics</i> , 2009, 41, 455-459.	21.4	322
6	How I treat hemophagocytic lymphohistiocytosis in the adult patient. <i>Blood</i> , 2015, 125, 2908-2914.	1.4	293
7	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. <i>Clinical Cancer Research</i> , 2019, 25, 4712-4722.	7.0	292
8	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
9	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 735-748.	27.6	234
10	Marked hyperferritinemia does not predict for HLH in the adult population. <i>Blood</i> , 2015, 125, 1548-1552.	1.4	170
11	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
12	Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. <i>British Journal of Haematology</i> , 2016, 172, 412-419.	2.5	119
13	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112
14	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 1624-1632.	7.0	103
15	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
16	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1471-1476.	6.4	74
17	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
18	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. <i>Annual Review of Medicine</i> , 2018, 69, 319-331.	12.2	61

#	ARTICLE	IF	CITATIONS
19	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by <i>NRG1</i> Gene Rearrangements. <i>Cancer Discovery</i> , 2022, 12, 1233-1247.	9.4	60
20	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 4066-4076.	7.0	45
21	The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i> -rearranged non-small cell lung cancers. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1983-1992.	2.0	43
22	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	1.9	39
23	Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring <i>NRG1</i> fusions. <i>Journal of Clinical Oncology</i> , 2021, 39, 3003-3003.	1.6	37
24	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , 2021, 11, 126-141.	9.4	34
25	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	1.6	32
26	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	13.2	29
27	Toward a More Precise Future for Oncology. <i>Cancer Cell</i> , 2020, 37, 431-442.	16.8	21
28	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	6.4	19
29	Precision oncology: Charting a path forward to broader deployment of genomic profiling. <i>PLoS Medicine</i> , 2017, 14, e1002242.	8.4	16
30	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.	1.4	15
31	Quantifying the Benefits of Genome-Driven Oncology. <i>Cancer Discovery</i> , 2017, 7, 552-554.	9.4	13
32	A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in <i>NRG1</i> fusion-positive advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3654-TPS3654.	1.6	10
33	AKT mutant allele-specific activation dictates pharmacologic sensitivities. <i>Nature Communications</i> , 2022, 13, 2111.	12.8	10
34	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.	5.2	8
35	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	3.0	8
36	Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. <i>Journal of Clinical Oncology</i> , 2017, 35, 131-134.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. <i>Cancer</i> , 2020, 126, 4967-4974.	4.1	6
38	Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2021, 5, 1187-1195.	2.4	5
39	Genetic and Functional Investigation of Germline JAK2 Alleles That Predispose to Myeloproliferative Neoplasms. <i>Blood</i> , 2011, 118, 124-124.	1.4	4
40	A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2602-TPS2602.	1.6	4
41	CD74-NRG1 Fusions Are Oncogenic <i>In Vivo</i> and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 821-830.	4.1	4
42	Hemophagocytic Lymphohistiocytosis: The Partners Healthcare Experience over the Past 8 Years. <i>Blood</i> , 2014, 124, 4104-4104.	1.4	2
43	Learning All That We Can From MyPathway. <i>Journal of Clinical Oncology</i> , 2018, 36, 2450-2451.	1.6	1
44	Marked Hyperferritinemia Does Not Predict for Hemophagocytic Lymphohistiocytosis (HLH) in the Adult Population. <i>Blood</i> , 2014, 124, 4951-4951.	1.4	0